0000899243-19-017822.txt : 20190621 0000899243-19-017822.hdr.sgml : 20190621 20190621171620 ACCESSION NUMBER: 0000899243-19-017822 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190619 FILED AS OF DATE: 20190621 DATE AS OF CHANGE: 20190621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JORDAN WADIH CENTRAL INDEX KEY: 0001222090 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 19912392 MAIL ADDRESS: STREET 1: ANTIGENICS INC. STREET 2: 162 FIFTH AVE., SUITE 900 CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-06-19 0 0001098972 AGENUS INC AGEN 0001222090 JORDAN WADIH C/O AGENUS INC. 3 FORBES ROAD LEXINGTON MA 02492 1 0 0 0 Stock Option, Right to buy 2.38 2019-06-19 4 A 0 2500 0.00 A 2020-01-01 2029-01-01 Common Stock 2500 2500 D Stock Option, Right to buy 2.38 2019-06-19 4 A 0 100000 0.00 A 2020-01-01 2029-01-01 Common Stock 100000 102500 D Option was granted on January 1, 2019, subject to shareholder approval of the Company's 2019 Equity Incentive Plan, which was obtained at the Company's annual shareholder meeting on June 19, 2019. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan. The option vests on January 1, 2020. /s/Evan D. Kearns, as Attorney-in-Fact for Wadih Jordan 2019-06-21